CHECKPOINT THER. DL-0001 (F:CZTA) — Market Cap & Net Worth
Market Cap & Net Worth: CHECKPOINT THER. DL-0001 (CZTA)
CHECKPOINT THER. DL-0001 (F:CZTA) has a market capitalization of $325.84 Million (€278.71 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #14623 globally and #1439 in its home market, demonstrating a 4.31% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CHECKPOINT THER. DL-0001's stock price €3.76 by its total outstanding shares 86320000 (86.32 Million).
CHECKPOINT THER. DL-0001 Market Cap History: 2020 to 2025
CHECKPOINT THER. DL-0001's market capitalization history from 2020 to 2025. Data shows growth from $207.94 Million to $378.94 Million (14.49% CAGR).
CHECKPOINT THER. DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CHECKPOINT THER. DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CZTA by Market Capitalization
Companies near CHECKPOINT THER. DL-0001 in the global market cap rankings as of May 5, 2026.
Key companies related to CHECKPOINT THER. DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
CHECKPOINT THER. DL-0001 Historical Marketcap From 2020 to 2025
Between 2020 and today, CHECKPOINT THER. DL-0001's market cap moved from $207.94 Million to $ 378.94 Million, with a yearly change of 14.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €378.94 Million | +15.01% |
| 2024 | €329.49 Million | +60.05% |
| 2023 | €205.87 Million | -46.57% |
| 2022 | €385.30 Million | +53.95% |
| 2021 | €250.27 Million | +20.36% |
| 2020 | €207.94 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of CHECKPOINT THER. DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $325.84 Million USD |
| MoneyControl | $325.84 Million USD |
| MarketWatch | $325.84 Million USD |
| marketcap.company | $325.84 Million USD |
| Reuters | $325.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CHECKPOINT THER. DL-0001
Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or m… Read more